Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: A multicenter study Journal Article


Authors: Castillo, J. J.; Beltran, B. E.; Bibas, M.; Bower, M.; Collins, J. A.; Cwynarski, K.; Diez-Martin, J. L.; Hernandez-Ilizaliturri, F.; Horwitz, S. M.; Montoto, S.; Pantanowitz, L.; Ribera, J. M.; Vose, J. M.
Article Title: Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: A multicenter study
Abstract: HIV infection has been associated with an increased risk of developing several types of malignancies, including aggressive peripheral T-cell lymphomas (PTCL). However, this is a rare occurrence with no more than a hundred cases reported in the literature. The purpose of this multicenter study is to describe the characteristics and to identify prognostic factors in patients with HIV-associated PTCL. Data from HIV-positive patients with a pathological diagnosis of non-primary cutaneous, non-leukemic PTCL were gathered retrospectively and are reported using descriptive statistics. Univariate and multivariate survival analyses were also performed. Fifty one patients were included in our analysis. Median age was 38 years with a 5:1 male-to-female ratio. Patients presented with a median CD4+ count of 173 cells mm-3, and a median HIV viral load of 334,787 copies ml-1. The median time from HIV diagnosis to PTCL diagnosis was 4.5 years. About 75% of patients presented with advanced clinical stage and 66% with B symptoms. The most common subtypes were PTCLU (61%) and anaplastic large cell lymphoma (ALCL, 22%). None of the ALCL patients tested expressed ALK. The median overall survival (OS) for the group was 12 months. In the multivariate survival analysis, the use of HAART and patients' performance status were independently associated with OS. HIV-associated PTCL presents predominantly in young men with low CD4+ counts and high HIV viral loads. Both HIV-related and lymphoma-related factors were associated with OS. © 2011 Wiley-Liss, Inc.
Keywords: adolescent; adult; cancer survival; middle aged; survival analysis; retrospective studies; young adult; major clinical study; overall survival; prednisone; cisplatin; doxorubicin; cancer combination chemotherapy; cytarabine; human immunodeficiency virus infection; carboplatin; dacarbazine; etoposide; cyclophosphamide; vincristine; retrospective study; sex ratio; ifosfamide; vinblastine; survival time; peripheral t cell lymphoma; disease severity; cd4+ t lymphocyte; bleomycin; vindesine; methylprednisolone; multivariate analysis; human immunodeficiency virus; large cell lymphoma; cd4 lymphocyte count; highly active antiretroviral therapy; virus load; antiretroviral therapy, highly active; lymphoma, aids-related; autologous hematopoietic stem cell transplantation; lymphocyte count; lymphoma, t-cell, peripheral; human immunodeficiency virus infected patient; viral load; hepatosplenic t cell lymphoma; anti human immunodeficiency virus agent; angioimmunoblastic lymphoma; enteropathy type t cell lymphoma; panniculitis like t cell lymphoma; peripheral t cell lymphoma unspecified
Journal Title: American Journal of Hematology
Volume: 86
Issue: 3
ISSN: 0361-8609
Publisher: John Wiley & Sons, Inc.  
Date Published: 2011-03-01
Start Page: 256
End Page: 261
Language: English
DOI: 10.1002/ajh.21947
PUBMED: 21328430
PROVIDER: scopus
DOI/URL:
Notes: --- - "Export Date: 23 June 2011" - "CODEN: AJHED" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    645 Horwitz